Olema Pharmaceuticals, Inc.
OLMANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for OLMA. That does not mean none is planned.
Get an email about OLMA's next catalysts
Track Olema Pharmaceuticals (OLMA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
OLMA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.60 | FQ end Sep/2026 | Call: tbd
How OLMA's past catalysts played out
Market Overview
Stock performance and key metrics
Palazestrant
Breast Cancer
Ribociclib
Breast Cancer
OP-1250
Hormone Receptor Positive Breast Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Palazestrant | Phase 3 | Breast Cancer | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
OP-1250 | Phase 2 | Hormone Receptor Positive Breast Carcinoma | - | - |
Frequently asked questions
What is in Olema Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Olema Pharmaceuticals, Inc.'s (OLMA) pipeline across Phase 3, Phase 2. Its lead program is Palazestrant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Olema Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Olema Pharmaceuticals, Inc. (OLMA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track OLMA biotech catalysts?→
Add OLMA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Olema Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.